1. Search Result
Search Result
Results for "

conduction

" in MedChemExpress (MCE) Product Catalog:

36

Inhibitors & Agonists

1

Screening Libraries

1

Fluorescent Dye

1

Peptides

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-106198

    IDD-676

    Aldose Reductase Metabolic Disease
    Lidorestat (IDD-676) is a potent, selective and orally active aldose reductase inhibitor with an IC50 of 5 nM. Lidorestat can be used for chronic diabetes complications. Lidorestat also improves nerve conduction and reduces cataract formation .
    Lidorestat
  • HY-B0563A
    Ropivacaine hydrochloride monohydrate
    5 Publications Verification

    Sodium Channel Potassium Channel Cardiovascular Disease Neurological Disease Cancer
    Ropivacaine hydrochloride monohydrate is a potent?sodium channel?blocker and blocks impulse conduction via reversible inhibition of?sodium ion influx?in nerve fibrese . Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane . Ropivacaine is widely used for regional anesthesia and neuropathic pain?management in vivo .
    Ropivacaine hydrochloride monohydrate
  • HY-B0563B
    Ropivacaine hydrochloride
    5 Publications Verification

    Sodium Channel Potassium Channel Cardiovascular Disease Neurological Disease Cancer
    Ropivacaine hydrochloride is a potent sodium channel blocker and blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese . Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane . Ropivacaine is widely used for neuropathic pain management in vivo .
    Ropivacaine hydrochloride
  • HY-B0563
    Ropivacaine
    5 Publications Verification

    Sodium Channel Potassium Channel Cardiovascular Disease Neurological Disease Cancer
    Ropivacain is a potent sodium channel blocker. Ropivacain blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese . Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane . Ropivacaine is used for the research of neuropathic pain management .
    Ropivacaine
  • HY-B0563C
    Ropivacaine mesylate
    5 Publications Verification

    Sodium Channel Potassium Channel Cardiovascular Disease Neurological Disease
    Ropivacaine mesylate is a long-acting amide local anaesthetic agent for a spinal block and effectively blocks neuropathic pain. Ropivacaine blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibressup>[1] . Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane .
    Ropivacaine mesylate
  • HY-119753

    SC-31828

    Others Cardiovascular Disease
    Disobutamide is an antianhythmic agent. Disobutamide slows conduction throughout the atrioventricular conduction system of the isolated perfused rabbit heart .
    Disobutamide
  • HY-118833

    Others Cardiovascular Disease
    RAC 109 is a local anesthetic. RAC 109 reduces ventricular conduction velocity and myocardial contractility in rabbits in a stereospecific manner (EC50=30 μM) .
    RAC 109
  • HY-105485

    Others Neurological Disease Metabolic Disease
    FR-62765 is a derivative of WF-3681. FR-62765 can significantly inhibit the accumulation of sorbitol in the sciatic nerve and the decrease of motor nerve conduction velocity in the tail of diabetic neuropathy rats, which can be used in the research of diabetic neuropathy .
    FR-62765
  • HY-130456

    Others Cardiovascular Disease
    AHR 10718 is an antiarrhythmic agent that suppresses cardiac arrhythmias induced by digitalis intoxication and myocardial infarction in the intact dog. AHR 10718 also depresses membrane responsiveness and conduction, shortens the effective refractory period of specialized conducting fibers less than action potential duration .
    AHR 10718
  • HY-B0563AR

    Sodium Channel Potassium Channel Cardiovascular Disease Neurological Disease Cancer
    Ropivacaine (hydrochloride monohydrate) (Standard) is the analytical standard of Ropivacaine (hydrochloride monohydrate). This product is intended for research and analytical applications. Ropivacaine hydrochloride monohydrate is a potent sodium channel blocker and blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese . Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane . Ropivacaine is widely used for regional anesthesia and neuropathic pain management in vivo .
    Ropivacaine hydrochloride monohydrate (Standard)
  • HY-B0563R

    Sodium Channel Potassium Channel Cardiovascular Disease Neurological Disease Cancer
    Ropivacaine (Standard) is the analytical standard of Ropivacaine. This product is intended for research and analytical applications. Ropivacain is a potent sodium channel blocker. Ropivacain blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese . Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane . Ropivacaine is used for the research of neuropathic pain management .
    Ropivacaine (Standard)
  • HY-B0563BS

    Isotope-Labeled Compounds Neurological Disease
    Ropivacaine-d7 hydrochloride is a deuterium labeled Ropivacaine (hydrochloride) (HY-B0563B) . Ropivacaine hydrochloride is a potent?sodium channel?blocker and blocks impulse conduction via reversible inhibition of?sodium ion influx?in nerve fibrese . Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane . Ropivacaine is widely used for neuropathic pain?management in vivo .
    Ropivacaine-d7 hydrochloride
  • HY-B1319

    Pramoxine hydrochloride

    Others Neurological Disease
    Pramocaine hydrochloride decreases the permeability of neuronal membranes to sodium ions, blocking both initiation and conduction of nerve impulses.
    Pramocaine hydrochloride
  • HY-145603A

    (R)-VX-121

    CFTR Others
    (R)-Vanzacaftor ((R)-VX-121) is a regulator of cystic fibrosis transmembrane conduction regulator (CFTR) .
    (R)-Vanzacaftor
  • HY-115839

    Tachmalcor free base

    Others Others
    Detajmium (Tachmalcor free base) is a Na?-channel blocker with activity to inhibit ventricular conduction and refractoriness. Detajmium (0.3μM) prolongs intraventricular conduction time comparable to propafenone (0.3μM) during sinus rhythm, but the time constant for reaching steady state during rapid ventricular pacing is significantly longer for Detajmium, indicating a unique temporal profile for its heart rate-dependent effects.
    Detajmium
  • HY-B1243
    Propoxycaine hydrochloride
    1 Publications Verification

    Sodium Channel Neurological Disease
    Propoxycaine hydrochloride inhibits voltage-gated sodium channels, and thereby inhibits the ionic flux required for the initiation and conduction of impulses. Propoxycaine hydrochloride application can lead to a loss of sensation.
    Propoxycaine hydrochloride
  • HY-B1319S1

    Pramoxine-d9 hydrochloride

    Isotope-Labeled Compounds Neurological Disease
    Pramocaine-d9 (hydrochloride) is deuterium labeled Pramocaine (hydrochloride). Pramocaine hydrochloride decreases the permeability of neuronal membranes to sodium ions, blocking both initiation and conduction of nerve impulses.
    Pramocaine-d9 hydrochloride
  • HY-B1007
    Butacaine
    2 Publications Verification

    Sodium Channel Others Neurological Disease
    Butacaine is a reversible nerve conduction blocker. Butacaine acts on the nervous system and nerve fibers, can cause both sensory and motor paralysis. Butacaine inhibits the NavBh currents .
    Butacaine
  • HY-117765

    Calcium Channel Cardiovascular Disease Neurological Disease
    RS-5773 is a calcium channel inhibitor and a diltiazem congener. RS-5773 has antianginal effect and does not cause excessive hypotension or depression of atrioventricular conduction .
    RS-5773
  • HY-B1319R

    Others Neurological Disease
    Pramocaine (hydrochloride) (Standard) is the analytical standard of Pramocaine (hydrochloride). This product is intended for research and analytical applications. Pramocaine hydrochloride decreases the permeability of neuronal membranes to sodium ions, blocking both initiation and conduction of nerve impulses.
    Pramocaine hydrochloride (Standard)
  • HY-119883

    Adrenergic Receptor Neurological Disease
    A-61603 free base is a potent adrenergic receptor agonist. A-61603 free base reduces carotid artery conductance in anesthetized pigs mediated by α1 and α2 adrenergic receptors (pEC50=7.25). A-61603 free base can be used as a probe to study adrenergic function .
    A-61603 (free base)
  • HY-135121

    Ethacizin; NIK-244

    Sodium Channel Cardiovascular Disease
    Ethacizine hydrochloride (Ethacizin; NIK-244) is a longer-lasting Class Ic antiarrhythmic agent than Flecainide . Ethacizine hydrochloride (Ethacizin; NIK-244) inhibits the depolarizing current responsible for the intraatrial and His-Purkinje-ventricular conduction .
    Ethacizine hydrochloride
  • HY-W243879

    DBP

    Others
    Tetraphenyldibenzoperiflanthene (DBP) is an organic semiconductor material with excellent electronic conduction activity. Tetraphenyldibenzoperiflanthene exhibits high mobility in organic field effect transistors (OFETs), improving device performance. Tetraphenyldibenzoperiflanthene is widely used in organic photovoltaic (OPV) materials to enhance photoelectric conversion efficiency.
    Tetraphenyldibenzoperiflanthene
  • HY-W803860

    Drug Metabolite Sodium Channel Cardiovascular Disease
    N-Depropylpropafenone is an active metabolite of Propafenone (HY-B0432), generated through the CYP450 enzyme system (mainly CYP2D6). It functions by blocking sodium ion channels, slowing myocardial conduction and exhibiting certain antiarrhythmic effects .
    N-Depropylpropafenone
  • HY-17611

    MSP-2017; (-)-MSP-2017

    Calcium Channel Cardiovascular Disease
    Etripamil (MSP-2017) is a short-acting L-type calcium-channel antagonist, can be used for the research of Paroxysmal Supraventricular Tachycardia (PSVT). Etripamil (MSP-2017) slows atrioventricular nodal conduction and prolongs atrioventricular nodal refractory periods by inhibiting calcium ion influx through the calcium slow channels in the atrioventricular node cells .
    Etripamil
  • HY-105093

    Adenosine Receptor Inflammation/Immunology
    N-0861 is a novel selective A1 adenosine receptor antagonist. In studies, it has been shown to be able to inhibit the negative conduction effects (prolonged AH interval) and chest pain caused by adenosine, while having no significant effect on the increase in coronary blood flow velocity caused by adenosine. This indicates that N-0861 has the property of selectively inhibiting A1 adenosine receptors .
    N 0861
  • HY-P2860A

    Cholinesterase (ChE) Neurological Disease
    Acetylcholinesterase, Electric eel is a cholinergic enzyme that is mainly found in neuromuscular junctions and cholinergic chemical synapses and is often used in biochemical research. Acetylcholinesterase, Electric eel can catalyze the decomposition or hydrolysis of acetylcholine and some other choline esters that act as neurotransmitters into acetic acid and choline. The main function of Acetylcholinesterase, Electric eel is to terminate neuronal transmission and signal conduction between synapses to prevent ACh diffusion and activation of nearby receptors .
    Acetylcholinesterase, Electric eel
  • HY-123196

    Adenosine Receptor Cardiovascular Disease
    CVT-2759 is a potent inhibitor of A1-ADOR, with the IC50 values of 0.18 μM and 9.5 μM to reduce the binding of [3H]CPX in the absence and presence of 1 mM GTP. CVT-2759 plays an important role in slowing AV nodal conduction and thereby ventricular rate without causing AV block, bradycardia, atrial arrhythmias, or vasodilation .
    CVT-2759
  • HY-B0563S1

    Isotope-Labeled Compounds Sodium Channel Potassium Channel Cardiovascular Disease Neurological Disease
    Ropivacaine-d7 is deuterium labeled Ropivacaine. Ropivacain is a potent sodium channel blocker. Ropivacain blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese[1][2]. Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane[3]. Ropivacaine is used for the research of neuropathic pain management[1].
    Ropivacaine-d7
  • HY-129763

    Fluorescent Dye Others
    Di-4-ANEPPS is a voltage-sensitive dye in membrane potential. Di-4-ANEPPS allows reaching a time resolution better than 1 ms and exhibits changes in fluorescence of up to 10% per 100 mV. Di-4-ANEPPS is a common tool for mapping cardiac electrical activity. Di-4-ANEPPS demonstrate significant direct irreversible effect on spontaneous heart rate and ventricular impulse conduction in rabbit isolated heart model .
    Di-4-ANEPPS
  • HY-167689

    Others Neurological Disease
    Parethoxycaine hydrochloride is an anesthetic with nerve conduction blocking activity. Parethoxycaine hydrochloride exhibits non-selective inhibitory effects on responses to various stimulants in rat vas deferens and guinea pig ileum muscles. Parethoxycaine hydrochloride has an enhanced effect on the action of norepinephrine, and its methyl bromide derivative also exhibits the same properties on the action of norepinephrine and potassium ions. Derivatives of parethoxycaine hydrochloride have significant effects on calcium dose-response curves, displaying different tissue and stimulant selectivities. The mechanism of action of Parethoxycaine hydrochloride involves the regulation of calcium transport processes .
    Parethoxycaine hydrochloride
  • HY-P4742A

    6-FAM-AEEAC-SHK TFA

    Biochemical Assay Reagents Potassium Channel Neurological Disease
    6-FAM-AEEAc-Stichodactyla helianthus Neurotoxin (ShK) TFA (6-FAM-AEEAC-SHK TFA) is a peptide neurotoxin conjugated with a fluorescent marker. 6-FAM-AEEAc-Stichodactyla helianthus Neurotoxin (ShK) TFA can block voltage-gated potassium channels (kv1.1 and kv1.2) to prolong the duration of action potentials, thereby affecting the conduction of neural signals. 6-FAM-AEEAc-Stichodactyla helianthus Neurotoxin (ShK) TFA can be used in neuroscience research .
    6-FAM-AEEAc-Stichodactyla helianthus Neurotoxin (ShK) (TFA)
  • HY-108998

    Others Cardiovascular Disease
    Bisaramil hydrochloride is an antiarrhythmic compound with activity in inhibiting free radical generation. Bisaramil hydrochloride directly blocks sodium currents and exhibits enhanced sodium channel blocking ability. Bisaramil hydrochloride inhibits isoproterenol-induced slow calcium action potentials in cardiomyocytes. Bisaramil hydrochloride reduces heart rate and prolongs the PR, QRS, and QT intervals in the electrocardiogram, showing blocking effects on sodium and potassium channels. Bisaramil hydrochloride reduces cardiac conduction velocity, increases the threshold current for capture and atrial fibrillation, and prolongs the effective refractory period. Bisaramil hydrochloride reduces ventricular arrhythmias and eliminates mortality caused by ventricular fibrillation in ischemic rat hearts .
    Bisaramil hydrochloride
  • HY-B0653A
    Levobupivacaine hydrochloride
    2 Publications Verification

    (S)-(-)-Bupivacaine monohydrochloride

    Sodium Channel Ferroptosis Cardiovascular Disease Neurological Disease Cancer
    Levobupivacaine hydrochloride ((S)-(-)-Bupivacaine monohydrochloride) is a long-acting amide local agent that can suppress or relieve pain. Levobupivacaine hydrochloride exerts agent that can suppress or relieve pain. and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine hydrochloride can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine hydrochloride is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine hydrochloride can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer .
    Levobupivacaine hydrochloride
  • HY-B0653

    (S)-(-)-Bupivacaine

    Sodium Channel Ferroptosis Neurological Disease Cancer
    Levobupivacaine ((S)-(-)-Bupivacaine) is a long-acting amide local agent that can suppress or relieve pain. Levobupivacaine exerts agent that can suppress or relieve pain. and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer .
    Levobupivacaine
  • HY-W585442

    Others
    5,9,14,18,23,27,32,36-Octabutoxy-2,3-naphthalocyanine is a photosensitive material with excellent light absorption and electron conduction activity. 5,9,14,18,23,27,32,36-Octabutoxy-2,3-naphthalocyanine is widely used in optoelectronic devices and is considered to be an effective photocatalyst. 5,9,14,18,23,27,32,36-Octabutoxy-2,3-naphthalocyanine can be used to improve the performance of solar cells and increase the photoelectric conversion efficiency. 5,9,14,18,23,27,32,36-Octabutoxy-2,3-naphthalocyanine also has potential anti-tumor activity and can inhibit the proliferation of certain cancer cells. 5,9,14,18,23,27,32,36-Octabutoxy-2,3-naphthalocyanine exhibits excellent fluorescence properties in medical imaging, which helps to improve the clarity and accuracy of imaging. 5,9,14,18,23,27,32,36-Octabutoxy-2,3-naphthalocyanine is studied as a component of a novel compound delivery system to improve the targeting and release effect of the compound.
    5,9,14,18,23,27,32,36-Octabutoxy-2,3-naphthalocyanine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: